Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

Here's what it means to Subaru owners.

Voyager Therapeutics, and Yumanity. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

EndeavorRx is also being tested for other indications, including 'brain fog' in COVID-19 survivors, and Akili has also started working on additional digital therapeutics for cognitive impairments ...

With the huge research investment worldwide, the peptide-based therapeutics market is expected to grow manifolds in the future. (2) There are several peptide-based drugs available in the market ...

Dyne Therapeutics Inc.-5.60% $1.56B ...